- 2024-08-20 02:17抑制剂Vistusertib|Vistusertib|1009298-59-2|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 02:17抑制剂Vistusertib|Vistusertib|1009298-59-2|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:17抑制剂Vistusertib|Vistusertib|1009298-59-2|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:17抑制剂Vipivotide tetraxetan|Vipivotide tetraxetan|1702967-37-0|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:17抑制剂Visomitin|Visomitin|934826-68-3|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 02:17抑制剂Visomitin|Visomitin|934826-68-3|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:17抑制剂Visomitin|Visomitin|934826-68-3|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:17抑制剂Vidofludimus|Vidofludimus|717824-30-1|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:17抑制剂Vimseltinib|Vimseltinib|1628606-05-2|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 02:17抑制剂Vimseltinib|Vimseltinib|1628606-05-2|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:17抑制剂Vimseltinib|Vimseltinib|1628606-05-2|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:17抑制剂Vicriviroc Malate|Vicriviroc Malate|541503-81-5|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:17抑制剂Vidofludimus|Vidofludimus|717824-30-1|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 02:17抑制剂Vidofludimus|Vidofludimus|717824-30-1|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:17抑制剂VGX-1027|VGX-1027|6501-72-0|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:17抑制剂VGX-1027|VGX-1027|6501-72-0|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:17抑制剂Vicriviroc Malate|Vicriviroc Malate|541503-81-5|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 02:17抑制剂Vicriviroc Malate|Vicriviroc Malate|541503-81-5|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:17抑制剂Verucerfont|Verucerfont|885220-61-1|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 02:17抑制剂Verucerfont|Verucerfont|885220-61-1|Adamas life|≥98%（以实测数值为准）|BR|25mg
